Doctors for Drug Policy Reform

Call Directions Website

Doctors for Drug Policy Reform Organizing Principles

Advocate for drug policies that are grounded in empirical evidence, public health, racial justice, equity, and human rights.

Mission
We are a global voice of licensed health professionals advocating for science-based drug policies and best practices that advance public health, reduce stigma, and minimize harm. Vision
Leverage the expertise, compassion, and influence of licensed medical professionals to enact changes in drug policy necessary to improve public health, human rights, social justice, and consumer protections. Promote science-based policies that recognize individual agency, respect bodily autonomy, and assure that people who use drugs are supported instead of punished. Advocate ongoing research and review of drug policies to verify their effectiveness, adapting policies as new evidence emerges. Promote practices for individuals experiencing problematic drug use that are evidence-based, minimize harm, and provide the resources necessary to maintain health and safety. Promote education and prevention efforts to ensure that our patients and the public are provided unbiased information regarding the potential benefits and harms of all drugs, including prevention education for minors. Engage in international collaboration to change global drug-related policies. Repair the harm to public health caused by past support of physicians for the war on drugs. Recognize the importance of Indigenous knowledge holders and the preservation of ancestral wisdom regarding plant medicine. D4DPR Platform

Our Platform will be represented by four overlapping areas of focus. Maximizing Health emphasizes the psychiatric and somatic benefits offered by presently prohibited medications. Harm Reduction provides clear and concise policy statements that will guide our approach to drug use and misuse. Cannabis continues our ongoing work on cannabis regulation and legalization. Psychedelics acknowledges the explosion of clinical research in psychedelic medicine. Maximizing Health
Access to health promoting interventions and treatment, both non-abstinence and abstinence based, to individuals with problematic drug use. Recognition of the potential health benefits of promising Schedule I drugs, including cannabis and psychedelics. Federal protection of licensed medical professionals providing evidence-based treatment with Schedule I drugs consistent with state laws, including the discussion of their benefits and risks. Harm Reduction
Empirically-supported harm reduction efforts (“meeting people where they are”) to promote public safety, protecting both individuals using drugs and society. Protection of the public and individuals through overdose prevention centers, syringe services, naloxone distribution, drug-checking, treatment (including opioid agonist therapies), Good Samaritan laws, and other evidenced-based interventions. Reduction/avoidance of penalties for drug possession and use. Cannabis
Government oversight of commercial cannabis production, testing, distribution, and sales
Detailed labeling of cannabis products with health and safety information
Prevention of non-medical underage cannabis use through:
o Child-resistant packaging
o A ban on packaging, marketing, and advertising that attracts underage users
Cannabis competency for all medical providers
Taxation of adult-use cannabis to fund equity programs for communities harmed by the drug war
Protected rights for limited home cultivation of cannabis
Expungement of cannabis arrests, charges, and convictions from criminal records
Diversity in all sectors of the cannabis industry
Reduce public health risks associated with overcommercialization

Psychedelics
Access to psychedelic medicine for all individuals, regardless of socioeconomic status. Protection of licensed medical professionals utilizing their scope of practice when conducting psychedelic-assisted therapy. Health-care coverage parity for psychedelic medicine. Our board feels passionate about our new path as we embark on this broader trajectory for our organization. We anticipate a comprehensive engagement that will confront the injustices, damages, and the rising toll of fatalities resulting from drug prohibition. We invite you to join us in our endeavor to foster a more empathetic, empirically-based, and deliberate approach to the complexities of drug use and misuse. If you are supportive of this expanded mission, we would also be grateful for a donation to support our efforts at this critical junction in our history. If you are already a dues-paying member, please consider increasing the level of your support.

The hearing is over. The comment period is not.The FDA is still accepting written public comments on the potential futur...
09/24/2026

The hearing is over. The comment period is not.
The FDA is still accepting written public comments on the potential future therapeutic use of psychedelic drugs.
📅 Deadline: October 5, 2026
⏰ 11:59 p.m. ET
If you have a perspective to share, now is the time to submit it.
Get informed. Get involved. Make your voice heard.

What should the future of psychedelic-assisted care consider?The FDA is seeking public perspectives on several important...
09/18/2026

What should the future of psychedelic-assisted care consider?
The FDA is seeking public perspectives on several important issues surrounding the potential future therapeutic use of psychedelic drugs.
Four broad areas highlighted include:
1️⃣ Provider training and credentialing
2️⃣ Promotion of patient safety
3️⃣ Considerations for access
4️⃣ Best practices for data collection and standardization
These questions involve more than the development of new treatments. They also raise important considerations about how potential therapies could be delivered safely, responsibly, and effectively.
Written public comments are open through October 5, 2026, at 11:59 p.m. ET.
Review the FDA information and consider sharing your perspective.

On September 14, the FDA held a public hearing on issues associated with the potential future therapeutic use of psyched...
09/15/2026

On September 14, the FDA held a public hearing on issues associated with the potential future therapeutic use of psychedelic drug products in supervised and supportive settings.
The hearing has concluded, but an important opportunity for public input remains.
Written public comments are being accepted through October 5, 2026, at 11:59 p.m. ET.
The FDA is seeking perspectives across four broad areas:
• Provider training and credentialing
• Promotion of patient safety
• Considerations for access
• Best practices for data collection and standardization
These are complex questions with implications for healthcare professionals, researchers, policymakers, advocates, patients, and other stakeholders.
If you have relevant experience, expertise, or perspective, consider contributing to the public record.
The conversation continues through written public comment.

Why are two effective treatments for opioid use disorder delivered through two profoundly different systems?Join Doctors...
09/03/2026

Why are two effective treatments for opioid use disorder delivered through two profoundly different systems?

Join Doctors for Drug Policy Reform for “Separate and Unequal,” a timely webinar examining how a century of drug policy created racially and socioeconomically segregated pathways to methadone and buprenorphine treatment.

Marco Antonio Ramos, MD, PhD, a historian and psychiatrist at Yale University, will trace this history and explain why understanding it is essential to expanding equitable, evidence-based care amid the ongoing overdose crisis.

📅 September 9, 2026
⏰ 6:30 PM ET / 3:30 PM PT
💻 Online webinar with audience Q&A
👥 Free for all: healthcare professionals, scientists, advocates, and interested community members

Register today: https://d4dpr.networkforgood.com/events/104489-health-advocacy-training-webinar-separate-and-unequal-methadone-buprenorphine-and-the-making-of-a-two-tiered-treatment-system

Don't miss our next Heath Advocacy Network training series webinar on September 9:  "Separate and Unequal: Methadone, Bu...
08/19/2026

Don't miss our next Heath Advocacy Network training series webinar on September 9: "Separate and Unequal: Methadone, Buprenorphine and the Making of a Two-Tiered Treatment System”

Dr. Marco Antonio Ramos, historian, psychiatrist, and Assistant Professor in the History of Medicine and Department of Psychiatry at Yale University, will provide this session detailing how a century of drug policy and legislation established a racially and socioeconomically segregated treatment system for opioid use disorder.

Learn more and sign up here: https://d4dpr.networkforgood.com/events/104489-health-advocacy-training-webinar-separate-and-unequal-methadone-buprenorphine-and-the-making-of-a-two-tiered-treatment-system

And it's not too late to sign up for our webinar TONIGHT, too- https://d4dpr.networkforgood.com/events/103548-health-advocacy-training-webinar-equity-in-ibogaine-research-for-opioid-use-disorder

Don't miss our next Health Advocacy Network & Physicians for Opioid Settlement Equity Training Series Webinar: August 19...
07/22/2026

Don't miss our next Health Advocacy Network & Physicians for Opioid Settlement Equity Training Series Webinar: August 19, 7pm EST/4pm PST!

Can an investment of opioid settlement funds generate evidence on emerging OUD treatments while strengthening the harm reduction services communities already rely on?

In this webinar, Richard Harris, PhD, will explore how small-scale, community-based pilot studies can help answer this question. Using ibogaine as an example, Dr. Harris will discuss a research approach that reflects the people clinicians actually treat, doesn't disrupt existing harm reduction services, and generates real-world evidence alongside care delivery.

Learn more and register here:

https://d4dpr.networkforgood.com/events/103548-health-advocacy-training-webinar-equity-in-ibogaine-research-for-opioid-use-disorder

📢 What makes science communication truly effective?Good science communication is about more than sharing facts. It's abo...
06/29/2026

📢 What makes science communication truly effective?

Good science communication is about more than sharing facts. It's about building trust, understanding audiences, and inspiring meaningful action.

In our recent webinar, Dr. Katherine Kennedy and Dr. Falisha Gilman shared five key elements that can help advocates, healthcare professionals, researchers, and communicators create greater impact:

✅ Know your audience
✅ Anticipate opposition
✅ Incorporate evidence
✅ Tell stories
✅ Make a clear ask

Whether you're communicating research findings, advocating for policy change, or engaging your community, these principles can help turn information into understanding and understanding into action.

Missed this session? You can find other educational videos from Doctors for Drug Policy Reform on our YouTube channel, and register for upcoming webinars at d4dpr.org/education.

A special thank you to Dr. Falisha Gilman for sharing her expertise during our Advocacy Network Training Series webinar ...
06/19/2026

A special thank you to Dr. Falisha Gilman for sharing her expertise during our Advocacy Network Training Series webinar on Science Communication Strategies and Testimony Tips.
Dr. Gilman emphasized the power of storytelling in advocacy and how personal experiences can help create connection, build empathy, and inspire action alongside evidence and research.
Thank you as well to everyone who joined us for this engaging discussion. By learning from one another and amplifying evidence-based messages, we can continue advancing more compassionate and effective drug policies.
#

Address

712 H Street NE Suite 1290
Washington D.C., DC
20002

Alerts

Be the first to know and let us send you an email when Doctors for Drug Policy Reform posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Sponsored

Share